DK1214091T3 - Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister - Google Patents

Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister

Info

Publication number
DK1214091T3
DK1214091T3 DK00961900T DK00961900T DK1214091T3 DK 1214091 T3 DK1214091 T3 DK 1214091T3 DK 00961900 T DK00961900 T DK 00961900T DK 00961900 T DK00961900 T DK 00961900T DK 1214091 T3 DK1214091 T3 DK 1214091T3
Authority
DK
Denmark
Prior art keywords
integrin antagonists
chronic kidney
kidney failure
failure therapies
risk
Prior art date
Application number
DK00961900T
Other languages
English (en)
Inventor
Roy Lobb
Andrew Allen
Charles Pusey
Original Assignee
Biogen Idec Inc
Imperial College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Imperial College filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1214091T3 publication Critical patent/DK1214091T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK00961900T 1999-09-14 2000-09-14 Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister DK1214091T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15382699P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
DK1214091T3 true DK1214091T3 (da) 2006-08-28

Family

ID=22548902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00961900T DK1214091T3 (da) 1999-09-14 2000-09-14 Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister

Country Status (13)

Country Link
US (3) US20030007969A1 (da)
EP (1) EP1214091B1 (da)
JP (3) JP4975922B2 (da)
AT (1) ATE325623T1 (da)
AU (1) AU783266B2 (da)
CA (1) CA2384948C (da)
CY (1) CY1105117T1 (da)
DE (1) DE60027907T2 (da)
DK (1) DK1214091T3 (da)
ES (1) ES2263485T3 (da)
NZ (1) NZ517781A (da)
PT (1) PT1214091E (da)
WO (1) WO2001019396A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
EP1610752B1 (en) 2003-01-31 2013-01-02 Boston Scientific Limited Localized drug delivery using drug-loaded nanocapsules and implantable device coated with the same
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
DE102009000854A1 (de) * 2009-02-13 2010-08-19 Ernst-Moritz-Arndt-Universität Greifswald Osteopontin-Rezeptor-Liganden zur Behandlung des chronischen Nierenversagens

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111657A (en) * 1977-01-21 1978-09-05 American Monitor Corporation Creatinine assay and reagent system
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DE69309487T2 (de) * 1992-11-13 1997-10-23 Univ Washington Peripheralisierung hämatopoietischer stammzellen
DE69419721T2 (de) * 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
SG124234A1 (en) * 1996-07-25 2006-08-30 Biogen Idec Inc Cell adhesion inhibitors
ATE359804T1 (de) * 1998-05-22 2007-05-15 Boys Town Nat Res Hospital Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2319831T3 (es) * 1998-09-14 2009-05-12 Board Of Regents, The University Of Texas System Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
US6245885B1 (en) * 1998-10-05 2001-06-12 Mcgill University Bax-mediated apoptosis modulating reagents and methods
EP2332578A1 (en) * 1999-12-16 2011-06-15 Biogen Idec MA Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists

Also Published As

Publication number Publication date
DE60027907T2 (de) 2007-01-04
US20030007969A1 (en) 2003-01-09
AU783266B2 (en) 2005-10-06
ES2263485T3 (es) 2006-12-16
CY1105117T1 (el) 2010-03-03
JP5463316B2 (ja) 2014-04-09
JP2013116916A (ja) 2013-06-13
JP2003509380A (ja) 2003-03-11
DE60027907D1 (de) 2006-06-14
JP4975922B2 (ja) 2012-07-11
NZ517781A (en) 2004-01-30
US20110305686A1 (en) 2011-12-15
CA2384948A1 (en) 2001-03-22
WO2001019396A1 (en) 2001-03-22
AU7379200A (en) 2001-04-17
EP1214091A1 (en) 2002-06-19
CA2384948C (en) 2013-07-16
JP2011116791A (ja) 2011-06-16
ATE325623T1 (de) 2006-06-15
PT1214091E (pt) 2006-09-29
EP1214091B1 (en) 2006-05-10
US20140234299A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
UA88440C2 (ru) ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β
ATE245997T1 (de) Therapien des chronischen nierenversagens
BR9913645A (pt) Terapias combinadas para linfomas de células b compreendendo a administração de anticorpo anti-cd20
DK1098874T3 (da) Benzocycloheptener, fremgangsmåder til deres fremstilling, farmaceutiske præparater, som indeholder disse, samt deres anvendelse til fremstilling af lægemidler
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
DE60031248D1 (de) Elektroaktive pore
DK0479903T3 (da) Substituerede imidazoler og deres anvendelse som angiotensin II hæmmere
DE60322527D1 (de) Rapiesystem
DK1304327T3 (da) Glutamin-thiazolidider og -pyrrolidider samt anvendelsen af disse som dipeptidylpeptidase-IV-inhibitorer
DK1339409T3 (da) Anvendelse af rosuvastatin (ZD-4522) til behandling af heterozygot, familiær hypercholesterolæmi
BR9915134A (pt) Co-terapia e terapia combinada para o tratamento de distúrbio cardiovascular em um indivìduo, e, composição
TR200200112T2 (tr) Fosfat taşıma ihtibitörleri
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK1228028T3 (da) Hydroxyicosatetraenoatsalte, præparater og fremgangsmåder til anvendelse til behandling af öjentörhedslidelser
DK1497330T3 (da) Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein
NO20052059L (no) Terapier for kronisk inflammatorisk demyeliniserende polynevropati ved anvendelse av interferon-beta.
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
DK1214091T3 (da) Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
DE69714451T2 (de) Prionbindende proteine und deren verwendungen
UY28345A1 (es) Compuestos novedosos
ATE258045T1 (de) Verfahren zu herstellung von pulverförmigen solubilisationshilfsstoffen für feste pharmazeutische darreichungsformen
DE502006002907D1 (de) Verbandsmaterial mit wirkstoffen
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
Samuels et al. Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy
WO2002029031A3 (en) Isoprenoid-dependent ras anchorage (idra) proteins